SEC Company Response from SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027) (VIRX) — Sep 27, 2005
SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027)
Date: Sept. 27, 2005 · CIK: 0001061027 · Accession: 0001104659-05-045802
AI Filing Summary & Sentiment
File numbers found in text: 333-121646
Show Raw Text
CORRESP
1
filename1.htm
September 26,
2005
Securities and Exchange
Commission
Division of
Corporation Finance
100 F Street, N.E.
Mail Stop 03-08
Washington,
D.C. 20549
Attention: Ms. Suzanne Hayes
Re: Sunesis
Pharmaceuticals, Inc.
Registration
Statement on Form S-1 (File No. 333-121646)
Ladies and Gentlemen:
As
representative of the undersigned underwriters of the proposed initial public
offering of up to 6,000,000 shares of common stock of Sunesis Pharmaceuticals,
Inc. (the “Company”), we hereby join the Company’s request for acceleration of
the above-referenced Registration Statement, requesting effectiveness for 9:00
A.M. (NYT) on September 27, 2005, or as soon thereafter as is practicable.
Pursuant to
Rule 460 of the General Rules and Regulations under the Securities Act of 1933,
as amended, we wish to advise you that we have effected the following
distribution of the Company’s Preliminary Prospectus dated September 1, 2005,
through the date hereof:
Preliminary Prospectus dated September 1, 2005:
8,328 copies
to prospective underwriters, institutional investors, dealers and others
The
undersigned advise that they have complied and will continue to comply with
Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly
yours,
LEHMAN
BROTHERS INC.
SG COWEN & CO., LLC
NEEDHAM
& COMPANY, LLC
BY:
SG COWEN
& CO., LLC
BY:
/s/
Graham Powiss
Graham
Powiss,
Managing
Director